Please login to the form below

Not currently logged in
Email:
Password:

tezacaftor

This page shows the latest tezacaftor news and features for those working in and with pharma, biotech and healthcare.

Setback for Vertex’s cystic fibrosis challenger Proteostasis

Setback for Vertex’s cystic fibrosis challenger Proteostasis

The data also included readouts from separate studies of PTI-801 and PTI-428 as add-on treatments to Vertex’s Symdeko/Symkevi (tezacaftor/ivacaftor) therapy in patients with cystic fibrosis.

Latest news

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics